Philipp Hoppe, Chemical Biology & Therapeutics

Co-Mentor: Miriam Bibel, PhD

Chemical Biology & Therapeutics

Basel, Switzerland

Our group is integrated into a multidisciplinary research department, and we apply our knowledge to unravel novel disease intervention points. The main aim of our group is to identify potential new drug targets and the molecular pathways that they are involved in. The team has in-depth knowledge in genome-wide genetic approaches and sequencing technologies.

Our general focus is on mammalian systems, using mutagenesis in cell lines, ES/iPS cell-derived progeny and organoids as well as primary cells, with the application of CRISPR/Cas9-mediated gene editing approaches being one of our central methods. We are constantly improving our technical know-how around genome-editing assays starting from simple survival-based, single knock-out screens up to multi-fate readouts of individual cells with simultaneous manipulation of several genes. In combination with flow cytometry and liquid handling equipment, we apply these tools to various disease models and are able to ask specific questions around a focused set of target genes or apply genome-wide methodologies.

We are mostly interested in research questions in the fields of hematopoiesis, immunology, regenerative medicine, and lineage choice of various stem cell systems with a particular focus on transcription factors, and we collaborate with other groups in these fields of expertise. Ultimately, we are trying to find molecules that allow us to manipulate cells in such a way that they contribute to attenuate or even cure diseases. We believe that combining the latest state-of-the-art methods with relevant scientific questions will lead us to new interesting discoveries.

Selected Publications

Prospective identification of hematopoietic lineage choice by deep learning.
Buggenthin F, Buettner F, Hoppe PS, Endele M, Kroiss M, Strasser M, Schwarzfischer M, Loeffler D, Kokkaliaris KD, Hilsenbeck O, Schroeder T, Theis FJ, Marr C.
Nat Methods. 2017 Apr;14(4):403-406.

Early myeloid lineage choice is not initiated by random PU.1 to GATA1 protein ratios.
Hoppe PS, Schwarzfischer M, Loeffler D, Kokkaliaris KD, Hilsenbeck O, Moritz N, Endele M, Filipczyk A, Gambardella A, Ahmed N, Etzrodt M, Coutu DL, Rieger MA, Marr C, Strasser MK, Schauberger B, Burtscher I, Ermakova O, Bürger A, Lickert H, Nerlov C, Theis FJ, Schroeder T.
Nature. 2016 Jul 14;535(7611):299-302.

Single-cell technologies sharpen up mammalian stem cell research.
Hoppe PS, Coutu DL, Schroeder T.
Nat Cell Biol. 2014 Oct;16(10):919-27.

Click here for additional publications.